CenterBook Partners LP Purchases Shares of 153,949 Ionis Pharmaceuticals, Inc. $IONS

Posted by George Bondi on Jun 8th, 2026

CenterBook Partners LP purchased a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 153,949 shares of the company’s stock, valued at approximately $12,179,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Grandfield & Dodd LLC raised its holdings in shares of Ionis Pharmaceuticals by 0.4% in the 4th quarter. Grandfield & Dodd LLC now owns 37,821 shares of the company’s stock valued at $2,992,000 after acquiring an additional 146 shares in the last quarter. Wedmont Private Capital raised its holdings in shares of Ionis Pharmaceuticals by 3.2% in the 4th quarter. Wedmont Private Capital now owns 5,536 shares of the company’s stock valued at $460,000 after acquiring an additional 173 shares in the last quarter. Prospera Financial Services Inc raised its holdings in shares of Ionis Pharmaceuticals by 3.9% in the 4th quarter. Prospera Financial Services Inc now owns 4,759 shares of the company’s stock valued at $376,000 after acquiring an additional 178 shares in the last quarter. Public Employees Retirement System of Ohio raised its holdings in shares of Ionis Pharmaceuticals by 0.6% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 48,545 shares of the company’s stock valued at $3,176,000 after acquiring an additional 301 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Ionis Pharmaceuticals by 37.5% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,137 shares of the company’s stock valued at $90,000 after acquiring an additional 310 shares in the last quarter. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Price Performance

Shares of Ionis Pharmaceuticals stock opened at $74.48 on Monday. The company has a current ratio of 4.10, a quick ratio of 4.09 and a debt-to-equity ratio of 2.75. The firm has a market capitalization of $12.31 billion, a PE ratio of -35.98 and a beta of 0.37. The business’s 50-day moving average price is $74.95 and its 200-day moving average price is $77.82. Ionis Pharmaceuticals, Inc. has a 12 month low of $34.78 and a 12 month high of $86.74.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.29. The firm had revenue of $246.09 million for the quarter, compared to analyst estimates of $195.57 million. Ionis Pharmaceuticals had a negative return on equity of 58.65% and a negative net margin of 30.91%.The company’s revenue was up 86.4% on a year-over-year basis. During the same period in the prior year, the company earned ($0.93) EPS. Sell-side analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.78 EPS for the current fiscal year.

Insider Activity

In related news, EVP Kyle Jenne sold 37,277 shares of the firm’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $75.85, for a total transaction of $2,827,460.45. Following the transaction, the executive vice president directly owned 11,714 shares in the company, valued at $888,506.90. This trade represents a 76.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Shannon L. Devers sold 6,193 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $74.05, for a total value of $458,591.65. Following the transaction, the executive vice president owned 16,348 shares in the company, valued at approximately $1,210,569.40. The trade was a 27.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 327,480 shares of company stock worth $24,030,004. 1.81% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms have weighed in on IONS. Needham & Company LLC raised their price target on Ionis Pharmaceuticals from $103.00 to $105.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Royal Bank Of Canada raised their price target on Ionis Pharmaceuticals from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, April 30th. Piper Sandler increased their price objective on Ionis Pharmaceuticals from $87.00 to $100.00 and gave the company an “overweight” rating in a research report on Friday, February 27th. Leerink Partners increased their price objective on Ionis Pharmaceuticals from $102.00 to $104.00 and gave the company an “outperform” rating in a research report on Tuesday, March 3rd. Finally, Wall Street Zen upgraded Ionis Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ionis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $100.90.

Check Out Our Latest Stock Report on IONS

About Ionis Pharmaceuticals

(Free Report)

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.